Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
Journal of the European Academy of Dermatology and Venereology · 2023
DOI: 10.1111/jdv.19468 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von Sonsoles Berenguer-Ruiz und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Universitario de la Princesa, Madrid, Spain. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Psoriasis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Background
Tildrakizumab is a humanized, IgG1/κ antibody that interacts with the p19 subunit of interleukin 23. It is approved for the treatment of moderate‐to‐severe plaque psoriasis. Real‐world evidence on the effectiveness and safety of tildrakizumab is limited.
Objectives
To assess the effectiveness and safety of tildrakizumab at 24 weeks in patients with moderate‐to‐severe plaque psoriasis in routine clinical practice.
Methods
Retrospective, observational, multicentre study including adult patients with moderate‐to‐severe plaque psoriasis treated with tildrakizumab under real‐life conditions. Patient data were extracted from anonymized electronic medical records. Statistical analysis was performed using SPSS22.
Results
A total of 190 patients were included. About 53.9% were men with a mean age of 51.45 (SD 3.9) and a mean BMI of 29.13 (SD 6.21). About 79.8% (132 out of 190) of patients had previously received biological therapy (BT) and 17.3% (33 out of 191) had psoriatic arthritis. Baseline PASI was 10.7 (SD 6.53). Up to 109 patients reached Week 24 and at this point mean baseline PASI decreased to 1.7 (SD 4.8), representing an 88.79% mean PASI reduction. At 6 months, 87.1% and 40.3% of the treated patients achieved PASI ≤3 and ≤1, respectively. At Week 24 mean BSA decreased from 13.2 (SD 10.07) to 1.6 (SD 4.40) and mean DLQI went from 12.5 (SD 7.12) to 1.2 (SD 3.27). Multivariate analysis showed no differences when effectiveness was correlated with gender, obesity, psoriatic arthritis or prior exposure to BT. The rate of adverse events (AE) was 5.9% (11 out of 190), where infections were the most frequent AE (4 out of 11). One patient suffered a haemorrhagic ictus and one patient died due to causes unrelated to the study.
Conclusion
Tildrakizumab was effective and safe in a large cohort of patients with moderate‐to‐severe plaque psoriasis treated in a routine clinical setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Hospital Universitario de la Princesa, Madrid, Spain.
- Department of Dermatology, Hospital Universitario La Paz, Madrid, Spain.
- Department of Dermatology, Hospital Universitario San Cecilio, Granada, Spain.
- Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
- Department of Dermatology, Hospital Universitario Central de Asturias, Oviedo, Spain.
- Department of Dermatology, Hospital Virgen del Rocio, Sevilla, Spain.
ORCID-Profile: Sonsoles Berenguer-Ruiz, Anna López-Ferrer, Salvador Arias-Santiago, Elena Del Alcázar, Isabel Belinchón-Romero, Álvaro González-Cantero, Diana Ruíz-Genao, Raquel Rivera-Diaz, Pablo de la Cueva, Esteban Daudén, Mar Llamas-Velasco
Zitieren
APA
Berenguer-Ruiz, S., Aparicio-Domínguez, M., Herranz-Pinto, P., Ruíz-Villaverde, R., López-Ferrer, A., Santos-Juanes, J., Rodríguez Fernández-Freire, L., Hospital-Gil, M., Arias-Santiago, S., Carretero-Hernández, G., Mateu-Puchades, A., Ferran, M., Del Alcázar, E., Santos-Alarcón, S., Garcia-Latasa de Aranibar, F. J., Belinchón-Romero, I., González-Cantero, Á., Ruíz-Genao, D., Eiris-Salvado, N., …, & Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology (2023). Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19468
Vancouver
Berenguer-Ruiz S, Aparicio-Domínguez M, Herranz-Pinto P, Ruíz-Villaverde R, López-Ferrer A, Santos-Juanes J, et al. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.19468
BibTeX
@article{BerenguerRuiz2023,
author = {Berenguer-Ruiz, Sonsoles and Aparicio-Domínguez, Mario and Herranz-Pinto, Pedro and Ruíz-Villaverde, Ricardo and López-Ferrer, Anna and Santos-Juanes, Jorge and Rodríguez Fernández-Freire, Lourdes and Hospital-Gil, Mercedes and Arias-Santiago, Salvador and Carretero-Hernández, Gregorio and Mateu-Puchades, Almudena and Ferran, Marta and Del Alcázar, Elena and Santos-Alarcón, Sergio and Garcia-Latasa de Aranibar, Francisco Javier and Belinchón-Romero, Isabel and González-Cantero, Álvaro and Ruíz-Genao, Diana and Eiris-Salvado, Noemí and Rocamora-Durán, Vicenç and Rivera-Diaz, Raquel and de la Cueva, Pablo and Daudén, Esteban and Salgado-Boquete, Laura and Llamas-Velasco, Mar and Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology, Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology},
title = {Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2023},
doi = {10.1111/jdv.19468}
}
EUVIMED